SEC Comment Letter for aTYR PHARMA INC (ATYR) (CIK 0001339970) (ATYR) — Feb 18, 2015
aTYR PHARMA INC (ATYR) (CIK 0001339970)
Date: Feb. 18, 2015 · CIK: 0001339970 · Accession: 0000000000-15-010065
AI Filing Summary & Sentiment
Reasoning
Letter
February 18, 2015 Via E -mail John D. Mendlein, Ph.D. Chief Executive Officer and Executive Chairman aTyr Pharma, Inc. 3545 John Hopkins Court, Suite #250 San Diego, CA 92121
Re: aTyr Pharma, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted February 2, 2015 CIK No. 0001339970
Dear Dr. Mendlein :
We have reviewed your amended draft registration statement and have the following comment.
Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to this comment and your amended draft registration statement or filed registration statement, we may have additional comments.
Prospectus Summary, page 1
1. We note on page 95 that you believe data from your Fc fusion experiments may produce data that will provide iModFc molecules for you to explore. We also note on page 96 that you are continuing to investigate potential therapeutic Physiocrines that may hav e the potential to inhibit inflammation in both the lung and the liver. As you do not have a drug candidate for your programs identified by the arrows labeled “iModFc non -RMIC,” “Liver,” or “Lung.” Please eliminate these programs from the pipeline table on pages 2 and 80.
John D. Mendlein, Ph.D. aTyr Pharma, Inc. February 18, 2015 Page 2
You may contact Mark Brunhofer at (202) 551 -3638 if you have questions regarding comments on the financial statements and related matters. Please contact Matthew Jones at (202) 551 -3786, Bryan Pitko at (202) 551 -3203 or me at (202) 551 -3715 with any other questions.
Sincerely,
/s/ Bryan J. Pitko for
Show Raw Text
February 18, 2015 Via E -mail John D. Mendlein, Ph.D. Chief Executive Officer and Executive Chairman aTyr Pharma, Inc. 3545 John Hopkins Court, Suite #250 San Diego, CA 92121 Re: aTyr Pharma, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted February 2, 2015 CIK No. 0001339970 Dear Dr. Mendlein : We have reviewed your amended draft registration statement and have the following comment. Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing the information you provide in response to this comment and your amended draft registration statement or filed registration statement, we may have additional comments. Prospectus Summary, page 1 1. We note on page 95 that you believe data from your Fc fusion experiments may produce data that will provide iModFc molecules for you to explore. We also note on page 96 that you are continuing to investigate potential therapeutic Physiocrines that may hav e the potential to inhibit inflammation in both the lung and the liver. As you do not have a drug candidate for your programs identified by the arrows labeled “iModFc non -RMIC,” “Liver,” or “Lung.” Please eliminate these programs from the pipeline table on pages 2 and 80. John D. Mendlein, Ph.D. aTyr Pharma, Inc. February 18, 2015 Page 2 You may contact Mark Brunhofer at (202) 551 -3638 if you have questions regarding comments on the financial statements and related matters. Please contact Matthew Jones at (202) 551 -3786, Bryan Pitko at (202) 551 -3203 or me at (202) 551 -3715 with any other questions. Sincerely, /s/ Bryan J. Pitko for Jeffrey P. Riedler Assistant Director cc: Kingsley L. Taft Maggie L. Wong Mitzi Chang Goodwin Procter LLP 3 Embarcadero Center, 24th Floor San Francisco, CA 94111